Myriad Genetics INC

Myriad Genetics reported a 11% year-over-year revenue decrease for Q2 2026, driven by lower average revenue per test and volume challenges in certain segments, while launching new initiatives for efficiency and scalability.

Myriad Genetics held its 2026 Annual Meeting, where stockholders approved amendments to equity incentive plans, increasing share availability for employees and directors.

Myriad Genetics reported first quarter 2026 revenue of $200.4 million, a 2% increase year-over-year, driven by growth in Cancer Care Continuum and Mental Health, while reiterating full-year 2026 financial guidance.

Myriad Genetics reported Q4 2025 financial results, showing revenue consistent with the prior year and growth in key test volumes, while reiterating 2026 financial guidance.

Myriad Genetics announced select unaudited preliminary results for the fourth quarter and full year 2025 and provided full year 2026 financial guidance.

Myriad Genetics reported third quarter 2025 financial results, with revenue of $205.7 million, and reaffirmed its full-year 2025 financial guidance.

Myriad Genetics reports a revenue decrease in Q2 2026 driven by estimate changes and reimbursement pressures, while increasing sales and marketing investments.

Myriad Genetics reported a 2.3% increase in revenue for the first quarter of 2026, reaching $200.4 million, but experienced a significant widening of its net loss to $34.1 million.

Myriad Genetics reported a wider net loss in the third quarter and first nine months of 2025, driven by significant goodwill and intangible asset impairment charges, despite some revenue growth in Hereditary Cancer and Prenatal segments.

Myriad Genetics reported a significant net loss in the second quarter of 2025, primarily driven by a $316.7 million goodwill and intangible asset impairment charge, despite slight revenue growth.

Myriad Genetics' Q1 2025 revenue decreased to $195.9 million, impacted by changes in pharmacogenomics coverage and leadership transitions.

Myriad Genetics saw an 11% year-over-year revenue increase in the third quarter of 2024, driven by growth in several testing segments, but faces potential revenue impacts due to a change in UnitedHealthcare's coverage policy for pharmacogenetic testing.

Myriad Genetics reported a significant net loss of $365.9 million in 2025, driven by substantial impairment charges and a 2% revenue decrease, despite strategic advancements in its testing portfolio.

Myriad Genetics announces its FY2024 financial results, highlighting revenue growth across key segments while addressing challenges related to reimbursement coverage.

Myriad Genetics has entered into a 15-year lease agreement for a new facility in Salt Lake City, with options for expansion and early termination under specific conditions.

Myriad Genetics President and CEO Samraat S. Raha acquired 3,542 shares of common stock through the company's employee stock purchase plan.

Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of Myriad Genetics common stock via the employee stock purchase plan.

Myriad Genetics Director Rashmi Kumar reported a sale of 15,000 shares of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Skovronsky was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the company's 2026 equity incentive plan.

Director Lee Nisley Newcomer was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Director Mark Steven Davis was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Myriad Genetics, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, to elect directors, ratify auditor selection, and approve executive compensation and equity plans.

Myriad Genetics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Myriad Genetics' proxy statement reveals a leadership transition with Sam Raha succeeding Paul Diaz as CEO, alongside strong 2024 financial performance and strategic advancements.

Myriad Genetics has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.

Myriad Genetics highlights 11% revenue growth in 2023 and strategic advancements in molecular diagnostics and precision medicine.

State Street Corporation has reported beneficial ownership of 4.7% of Myriad Genetics Inc. common stock as of March 31, 2026.

BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 7,976,163 shares, representing 8.5% of Myriad Genetics Inc.'s common stock.

The Vanguard Group has reported a 0% beneficial ownership in Myriad Genetics Inc. following an internal realignment.

Millennium Management LLC and affiliated entities, including Israel A. Englander, have disclosed a combined beneficial ownership of 7.2% in Myriad Genetics, Inc. common stock.

State Street Corporation has reported a 6.4% beneficial ownership stake in Myriad Genetics Inc. common stock as of December 31, 2025.

Glenview Capital Management and Larry Robbins have reported a 5.3% passive beneficial ownership stake in Myriad Genetics Inc. common stock.